ClinicalTrials.gg
CompletedNCT01076478ASCENDUpdated Feb 26, 2010

Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines

A Phase 4 interventional study of Cilostazol in Polyneuropathy, sponsored by Otsuka Pharmaceutical, Inc., Philippines. Completed at 1 site in Philippines. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2010-02-26.

Sponsored by Otsuka Pharmaceutical, Inc., Philippines (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

To describe if there are differences in the subjective, objective and electrophysiologic parameters of diabetic polyneuropathies at baseline, four (4) weeks, eight (8) weeks, and twelve (12) weeks after Cilostazol therapy.

02

Conditions studied

  • Polyneuropathy

Browse trials for

Keywords

  • Symmetric Diabetic Polyneuropathy
03

In context

Polyneuropathies

133 studies on the registry are indexed under Polyneuropathies; 33 are open to participants now.

This study's enrollment of 47 is below the median of 63 across 70 interventional studies indexed under Polyneuropathies.

Browse Polyneuropathies studies →

Lead sponsor

Otsuka Pharmaceutical, Inc., Philippines is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed written 2. Male and Female ages 18 to 70 years old. To be able to eliminate Type I Diabetes Mellitus among the younger subjects, we will only recruit patients who are stable on oral hypoglycemic agent. 3. Established diagnosis of diabetes mellitus type 2 (National Diabetes Data Group) who are currently on good control of the diabetic state.
  1. Presence of predominantly distal symmetrical sensory polyneuropathy of the lower limbs as assessed by NSS, NIS and NCS.

Exclusion criteria

Exclusion Criteria:

  1. Current use of potentially neuropathic agents (Isoniazid, Phenytoin, Dapsone, Metronidazole, Vinca Alkaloids, etc.) within the past 1 month;
  2. Presence of severe metabolic disease (renal failure, hepatic failure, etc.), alcoholism and ;
  3. Presence of hemorrhagic tendencies;
  4. Patients who are diagnosed to be of Type 1 Diabetes Mellitus;
  5. Pregnant and lactating patients, including those who plan to have pregnancy within the study period.
  6. Concomitant intake of agents currently used to treat neuropathic pain like gabapentin, carbamazepine/ oxcarbazepine, anti-depressants (tricyclic anti-depressants and SSRIs) and topical capsaicin.
  7. Concomitant intake of other anti- agents, rheologic agents and anticoagulants.
  8. Have received Cilostazol therapy within the past three (3) months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
47 participants (actual)

Study arms

  • Placebo comparator
    Arm 1

    2 tablets BID

    Drug: Cilostazol

  • Experimental
    Arm 2

    100 mg Cilostazol (2 tablets BID)

    Drug: Cilostazol

  • Experimental
    Arm 3

    200 mg Cilostazol (2 Tablets BID)

    Drug: Cilostazol

Interventions

  • 100 mg, 200mg tablet Cilostazol

    Also known as: Cilostazol, Pletaal, Pletal

06

What researchers measure

Primary outcomes

  1. Subjective neuropathy assessment by NSS (Neuropathy Symptom Scores)from Baseline (BS) to week 12 (W12) after Cilostazol therapy of the three (3) arms of the study.

    Time frame: 12 weeks

  2. Objective neuropathy assessment by NIS (Neuropathy Impairment Scores)from Baseline (BS) to week 12 (W12) after Cilostazol therapy of the three (3) arms of the study.

    Time frame: 12 weeks

  3. Electrophysiologic assessment by NCS (Nerve Conduction Studies) from Baseline (BS) to week 12 (W12) after Cilostazol therapy of the three (3) arms of the study.

    Time frame: 12 weeks

  4. To determine the relationship of peripheral neuropathy with peripheral vascular disease using the WIQ and the ABI from baseline to W12.

    Time frame: 12 weeks

Secondary outcomes

  1. To determine if there is improvement in subjective parameters of neuropathy as assessed by NSS and NSC (Neuropathy Symptoms and Change Questionnaire) from baseline to week 4 (W4), week 8 (W8) and week 12 (W12) after Cilostazol therapy.

    Time frame: 12 weeks

  2. To determine if there is improvement in objective parameters using NIS and NCS from baseline to W4, W8 and W12 after Cilostazol therapy.

    Time frame: 12 weeks

  3. To compare the effectivity of low dose (100mg) and high dose (200mg) Cilostazol based on subjective (NSS, NSC) and objective parameters (NIS, NCS) from baseline, to W4, W8 and W12.

    Time frame: 12 weeks

  4. To assess the safety of Cilostazol therapy.

    Time frame: 12 weeks

07

Study locations

1 site
  • University of Santo Tomas Hospital
    Manila, Philippines
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2004 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2010
First posted
Feb 26, 2010
Start
Mar 2004
CompletionActual
Nov 2009
Last update
Feb 26, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01076478
First posted
Feb 26, 2010
Start date
Mar 2004
Completion
Nov 2009
Last update
Feb 26, 2010

Study contacts

Raymond Rosales, MD, PhD
principal investigator · University of Santo Tomas Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cilostazol

Start the discussion